[403] developed ROR1‐targeting DACs that showed enhanced tumor‐specific BRD4 degradation and improved antitumor efficacy in PC3 and MDA–MB‐231 xenograft models, with superior pharmacokinetic profiles including extended half‐life compared with unconjugated PROTACs. This evidence concerns the gene BRD4 and neoplasm.